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ABSTRACT
Breast cancer is the most frequent malignancy in women. Several reports 
demonstrated that adrenergic receptors (ARs) are involved in breast cancer. Here 
we observed that epinephrine (Epi), an endogenous AR agonist, caused opposite 
effects in non-tumorigenic (MCF-10A and HBL-100) and tumor cells (MCF-7 and MDA-
MB-231). Thus, Epi, in non-tumor breast cells, as well as isoproterenol (β-agonist), 
in all cell lines, maintained a benign phenotype, decreasing cell proliferation and 
migration, and stimulating cell adhesion. β-AR expression and cAMP levels were 
higher in MCF-10A than in MCF-7 cells. β2-AR knock-down caused a significant 
increase of cell proliferation and migration, and a decrease of cell adhesion both in 
basal and in Iso-stimulated conditions. Coincidently, β2-AR over-expression induced 
a significant decrease of cell proliferation and migration, and an increase of cell 
adhesion. Therefore, β2-AR is implied in cell phenotype and its agonists or antagonists 
could eventually complement cancer therapy.
INTRODUCTION
Breast cancer is the most frequent malignancy in 
women worldwide, accounting for 23% of cancers in 
women, and the main cause of cancer death in women 
in both developing and developed countries. In USA, 
however, lung cancer has surpassed breast cancer 
mortality in women around 1990 [1, 2]. The molecular 
profiling of different subtypes of breast cancer greatly 
improved treatments and outcomes for patients [3].
Stress response is mediated primarily by the 
hypothalamic-pituitary-adrenocortical axis and the 
autonomic nervous system [4]. Epinephrine (Epi, also 
known as adrenaline) and Norepinephrine (NEpi, or 
noradrenaline) are classic neurotransmitters that mediate 
stress responses from the autonomic nervous system 
(a mechanism usually stated as “fight or flight” response). 
These catecholamines bind to three types of adrenergic 
receptors (ARs), subdivided in 9 different subtypes: 
α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, β3 [5]. ARs belong to 
the G protein-coupled receptors (GPCRs), which regulate 
several physiological and pathological conditions. The 
stimulation of β2-AR leads to Gs-dependent adenylyl 
cyclase activation and cAMP production which activates 
protein kinase A (PKA) and exchange protein directly 
activated by cAMP (Epac). Also, desensitization of β2-AR 
is mediated by GPCR kinase-dependent phosphorylation, 
followed by the recruitment of β-arrestins, independent 
signal transducers [6].
The β-AR pathway has been implied in different 
processes of cancer initiation and progression [7]. It has 
been previously shown both by us and other researchers, 
that β-AR stimulation was associated to an inhibition 
of cancer cell proliferation and tumor growth [8–10]. 
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However, β-blockers showed a similar inhibition of these 
parameters [11]. In addition, breast cancer cell motility 
is modified by adrenergic compounds in a cell-context 
manner, either enhancing or inhibiting this parameter 
[12, 13]. Our group has recently investigated the effect 
of the β-agonist isoproterenol (Iso) in non-tumorigenic 
human breast MCF-10A cells. Iso significantly diminished 
cell proliferation by a β2-AR/Gs/cAMP/PKA/Erk1/2 
pathway and also caused a significant enhancement of cell 
adhesion mediated mainly by β2-AR/Gs/cAMP/Epac [14]. 
In the last decades, β-ARs have gained great importance 
in breast cancer treatment due to β-blockers, mainly 
propranolol, being used in the treatment of patients with 
very promising outputs [15, 16].
Altogether, these previous findings encouraged us 
to study the role of β-AR in cell proliferation, adhesion 
and migration, key processes of tumor progression. For 
this purpose, tumor (MCF-7 and MDA-MB-231) and non- 
tumorigenic (MCF-10A and HBL-100) human breast 
cell lines were used. Both tumor cell lines were selected 
because they represent opposite breast cancer phenotypes. 
MCF-7 as a luminal A model, that accounts for more 
than 30% of breast cancer patients, and MDA-MB-231, 
previously considered basal-like, but now reclassified 
within the claudin-low subtype, corresponds to around 
10% of breast tumors [17]. Our study demonstrated for 
the first time that β2-AR expression is implicated in breast 
cell phenotype, suggesting that this receptor might be an 
important indicator of cell malignancy and consequently 
of tumor progression.
RESULTS
As epinephrine (Epi) is the endogenous AR ligand 
that binds to all ARs, we assessed its action on different 
parameters linked to breast cancer progression, such as 
proliferation, adhesion and migration. Cell proliferation 
was measured by [3H]-Thymidine incorporation in non-
tumorigenic MCF-10A and HBL-100 cell lines, and 
in breast tumor cell lines MCF-7 and MDA-MB-231 
(Figure 1A). Both Epi concentrations (1 nM and 1 μM) 
caused a significant inhibition of cell proliferation in the 
non-tumorigenic cells, whereas it significantly increased 
cell proliferation at a concentration of 1 μM in the cancer 
cells. We previously demonstrated in several human breast 
cell lines that Epi induced proliferation through α2-AR 
stimulation [9, 18]. On the other hand, Isoproterenol (Iso), 
a β-AR agonist, significantly decreased cell proliferation 
in every cell line (p<0.01, Figure 1B).
The effect of adrenergic compounds on cell 
adhesion was next evaluated by quantifying the percentage 
of cells remaining adherent to the plastic dishes following 
a specific cell detachment treatment as described in 
Materials and Methods. In non-tumorigenic breast cells 
MCF-10A, treatment with Epi resulted in a large and 
significant increase in the proportion of adhesive cells 
(Figure 2A). As Epi binds to α2 and to β-AR, which 
have been described in both tumor and non-tumorigenic 
breast cell lines [14, 18, 19], an agonist of each receptor 
type was also used in order to identify through which 
receptor Epi exerts this action. The significant increase 
of cell adhesion caused by Epi in non-tumorigenic cells 
at both concentrations was mimicked by the treatment 
with the β-adrenergic agonist Iso (p<0.01), but not by the 
α2-adrenergic agonist Dexmedetomidine (Dex) 
(Figure 2A). Similar results were observed in the non-
tumorigenic breast cell line HBL-100 (Figure 2C). 
Coincidently with this finding, in MCF-10A cells, 
1 μM Epi and Iso significantly inhibited cell migration 
(Figure 2B). In HBL-100 cells, Iso caused a significant 
decrease of cell migration, although no significant 
differences were observed with Epi treatment. In addition, 
Dex had no effect in either cell line on attachment or 
migration (Figure 2A-D).
In MCF-7 cells, Iso caused a moderate though 
significant increase in cell adhesion (p<0.001, Figure 2E), 
with a coincident inhibition of cell migration (p<0.05, 
Figure 2F). However, even if no effect on cell adhesion 
was evident in the presence of Epi or Dex in MCF-7 cells 
(Figure 2E), the lower concentration of Epi as well as 
Dex significantly increased cell migration (Figure 2F). 
In MDA-MB-231 cells the effects of Iso and Dex were 
opposite, and therefore, Epi which binds to both kinds 
of receptor showed no differences in cell adhesion 
(Figure 2G). In these cells, cell migration was significantly 
increased by Dex treatment (Figure 2H).
So far, we demonstrated an inhibition of cell 
proliferation and migration and an increase of adhesion 
when the non-tumor and tumor cells were incubated 
with Iso. Due to the previously mentioned importance of 
β-AR in cancer biology and our results, we next focused 
particularly on this receptor. Since the stimulation of β-AR 
causes an increase in cAMP levels, we determined its 
levels after 1 μM Iso treatment. Intracellular cAMP levels 
were studied in all cell lines in the presence or absence 
of the phosphodiesterase (PDE) inhibitor 3-isobutyl-
methylxantine (IBMX) (Figure 3A and B). Without IBMX, 
the peak concentration was coincident at 2.5 minutes. 
However, the non-tumorigenic breast cell lines, MCF-
10A and HBL-100, exhibited higher levels of cAMP than 
the cancer MCF-7 and MDA-MB-231 cells (Figure 3A). 
When the total area under the curves was evaluated 
with or without IBMX, non-tumorigenic cells exhibited 
higher cAMP levels than tumor cell lines (Figure 3B). As 
MCF-10A and MCF-7 cells are suitable models of non-
tumorigenic and tumor cell lines respectively, and they 
showed the highest cAMP levels within each group, they 
were chosen for further experiments.
In order to explain the results shown in Figure 1 
and 2, where Epi acts differentially in non-tumor vs tumor 
breast cell lines, we determined the number of β-AR in 
MCF-10A and MCF-7 cells by binding assays. The β-AR 
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levels were higher in MCF-10A than in MCF-7 cells 
(MCF-10A: 132 ± 21x103 vs MCF-7: 80 ± 5.5x103 sites/
cell, p<0.05). Furthermore, we previously reported the 
number of α2-binding sites/cell was higher in MCF-7 than 
in MCF-10A (MCF-7: 103 ± 23 x103 vs MCF-10A: 19 ± 
3.5 x103 sites/cell) [18].
To evaluate β-AR desensitization, we studied the 
ability of this receptor to continue producing cAMP after 
a stimulus. Cells were incubated at different times in the 
presence of 1μM Iso (without IBMX) washed with cold 
PBS and re-stimulated for 10 minutes (with IBMX). 
cAMP levels were then measured [20]. No differences 
were found in desensitization between both cell lines 
(Figures 3C and D). These results confirm that the higher 
cAMP levels observed in MCF-10A compared with MCF-
7 cells (Figure 3A) were due to the differences in β-AR 
Figure 1: Effect of epinephrine (Epi) and isoproterenol (Iso) on MCF-10A, HBL-100, MCF-7 and MDA-MB-231 cell 
proliferation. (A) Cells were stimulated or not (-) with 1 nM or 1 μM Epi or (B) 1 μM Iso and cell proliferation was evaluated by DNA 
synthesis using [3H]-Thymidine incorporation assay. The values are expressed as a percentage of the control in the absence of agonists. 
Data represent the mean ± s.e.m. of three independent experiments. Statistical significance was assessed using (A) ANOVA followed by a 
Dunnett’s test or (B) unpaired Student’s t-test.* p<0.05, **p<0.01.
Oncotarget10061www.impactjournals.com/oncotarget
Figure 2: Effect of adrenergic compounds on cell adhesion and migration in MCF-10A, HBL-100, MCF-7 and MDA-
MB-231 cells. (A, C, E and G) Cells were stimulated or not (Control) for 15 min with 1 nM or 1 μM epinefrine (Epi), 1 μM isoproterenol 
(Iso, β-AR agonist) and 1 μM dexmedetomidine (Dex, α2-AR agonist) and treated with the specific cell detachment buffer as described 
in the Materials and Methods section. Results are expressed as the percentage of cell number remaining adherent to the plastic dishes 
following specific cell detachment treatment. (B, D, F and H) Cell migration was measured by transwell assay treated during 16 hs with 
the same drugs as before. Data represent the mean ± s.e.m. of three independent experiments. Statistical significance was assessed using 
ANOVA followed by a Dunnett’s test.* p<0.05, **p<0.01, ***p<0.001.
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Figure 3: cAMP levels in tumor and non-tumorigenic breast cells. (A)Time course of intracellular cAMP production in MCF-
10A, HBL-100, MCF-7 and MDA-MB-231 cells in the absence of IBMX. (B) Comparison of the total production of cAMP (area under the 
curve obtained in A) after 1 μM isoproterenol stimulation in the presence (+) or absence (-) of 1 mM IBMX. (C and D) Desensitization of 
β-AR in MCF-10A cells (C) or MCF-7 cells (D). (E) cAMP concentration-response curves to Epinephrine (Epi) in MCF-10A and MCF-7 
cells with 1 mM IBMX. Data represent the mean ± s.e.m. of three independent experiments. Statistical significance was assessed using 
ANOVA followed by Bonferroni (B) or Dunnett’s test (E).* p<0.05, **p<0.01, ***p<0.001.
expression and not to a differential desensitization rate of 
this receptor.
In order to evaluate the effect of Epi, the natural 
agonist of AR, on cAMP production, concentration-
response curves were also performed. The incubation of 
MCF-10A cells with increasing concentrations of Epi 
elicited a marked enhancement of cAMP concentrations 
(in the presence of IBMX) while the incubation of MCF-7 
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cells did not change cAMP levels (Figure 3E). This last 
result on cAMP production could be explained by the high 
expression of α2-AR in this cell line, which classically 
couple to Go/i protein, inactivating adenylyl cyclase [18].
Since the β2-AR is the most expressed β-AR subtype 
in breast cell lines, including MCF-10A and MCF-7 cells 
[14, 19, 21, 22], we modified the expression levels of this 
receptor and evaluated its effect on proliferation, adhesion 
and migration. Cells were transfected either with a small 
interference RNA (siRNA) for knocking down β2-AR 
expression [23], or with a human β2-AR plasmid [24] for 
over-expressing it. As controls, both cell lines were also 
transfected with a scrambled siRNA (sc) or an empty vector 
(mock). β2-AR concentrations were analysed by binding 
assays (Figure 4A for MCF-10A and 4C for MCF-7) 
and receptor functionality was studied by measuring cAMP 
levels. As shown in Figure 4B, when modifying β2-AR 
levels in MCF-10A cells, cAMP basal concentrations did 
not change. However, the Iso-stimulated concentrations 
of cAMP were highly dependent on the β2-AR expression 
levels (Figure 4B). In MCF-7, β2-AR knock-down 
abrogated Iso cAMP stimulation (Figure 4D). Moreover, 
β2-AR over-expression caused a significant increase of 
cAMP levels in both basal and Iso-stimulated conditions, 
showing the important basal activity of the receptor.
When we evaluated parameters related to tumor 
phenotype in MCF-10A and MCF-7 cells, we found that 
β2-AR knock-down caused a significant increase in cell 
proliferation and migration, and a decrease in cell adhesion 
not only in basal but also in Iso-stimulated conditions 
(Figure 5). In line with this, β2-AR over-expression 
induced a significant decrease in cell proliferation and 
migration, and an increase in cell adhesion (Figure 5). 
Since β2-AR over-expression mainly affected basal 
conditions, no differences were observed when cells were 
stimulated with Iso.
Figure 4: β2-AR overexpression and knock-down in MCF-10A and MCF-7 cells. (A) Quantification of β2-AR in MCF-10A 
and (C) MCF-7 cells transfected with scrambled siRNA (sc), β2-AR-targeted pooled siRNA (siRNA), pcDNA3.1 (mock) or the plasmid 
codifying for the β2-AR. Panels A and C depict the saturation analysis performed with the β-AR radioligand [3H]-GCP 12177. The results 
are expressed as the percentage of the scrambled or the mock in whole cells at 4 °C. The modification of the expression of β-AR in the cells 
is shown in insets as a percentage of the sc or mock. (B) Total cAMP production in MCF-10A cells or (D) MCF-7 cells transfected with sc, 
siRNA, mock or β2-AR and incubated or not (control) with 1 μM Isoproterenol (Iso). Data represent the mean ± s.e.m. of two independent 
experiments. Statistical significance was assessed using ANOVA followed by a Bonferroni test. *** p<0.001.
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DISCUSSION
Catecholamines, epinephrine (Epi) and 
norepinephrine (NEpi), are released during both acute 
and chronic stress. Their functions are mediated through 
binding to adrenergic receptors (AR). Classically, these 
receptors were associated with the regulation of body 
homeostasis in health and disease, including cardiac and 
neurologic function. In the last decade, several reports 
reinforced the idea that ARs have an implication in 
cancer biology [25, 26]. It was shown that these receptors 
are involved in breast cancer progression. In particular, 
more than two decades ago, β-ARs were described in 
breast cancer cells in human and in experimental models 
[19, 27]. Since then, controversial results have been found 
with respect to agonist action on several parameters 
related to breast tumor progression, as reviewed in 
[28]. Numerous studies have shown an inhibition of 
cell proliferation and cell migration by β-AR agonists 
[8, 9, 13, 29]. Interestingly, β-blockers, commonly used 
as antihypertension drugs, have also been identified as 
decreasing cell proliferation and cell migration in estrogen 
receptor positive and negative breast cancer cells [14, 15], 
but also in other tumor types, including lung, pancreas, 
prostate, colon, stomach and ovarian cancer [30]. These 
controversial actions between β-agonists and β-blockers 
could be explained by the presence of polymorphism 
in the β2-AR gene or due to the recently discovery 
Figure 5: Effect of β2-AR expression on cell proliferation, adhesion and cell migration in MCF-10A and MCF-7 cell 
lines. Cells were transfected with scrambled siRNA (sc), β2-AR-targeted pooled siRNA (siRNA), pcDNA3.1 (mock) or the plasmid 
codifying for the β2-AR. The results are expressed as the percentage of the sc or mock. Panels A and B: cells were stimulated or not 
(Control) with 1 μM Isoproterenol (Iso) and cell proliferation was evaluated by automatic cell-counting. Panels C and D: cells were 
stimulated or not (Control) for 15 min with 1 μM Iso and treated with the specific cell detachment buffer as described in Materials and 
Methods. Results are expressed as the percentage of cell number remaining adherent to the plastic dishes following specific cell detachment 
treatment. Panels E and F: cell migration was measured by transwell assay treated or not (Control) with 1 μM Iso during 16 hs. Data 
represent the mean ± s.e.m. of three independent experiments. Statistical significance was assessed using ANOVA followed by a Bonferroni 
test.* p<0.05, **p<0.01, ***<p0.001.
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that some β-blockers have β-arrestin–biased agonism 
activity [30, 31]. Recently, an α1-blocker, also used as an 
antihypertension drug, inhibited tumor growth by reducing 
vascularization in an ovarian cancer model [32].
Due to the relevance of β-AR expression and 
activation in cancer, we first aimed on studying the role 
of Epi in tumor (MCF-7 and MDA-MB-231) and non-
tumorigenic (MCF-10A and HBL-100) human breast 
cell lines. The MCF-7 cell line was obtained from a 
pleural effusion of a human breast cancer [33] and is 
a paradigm of luminal A cells [17]. On the other hand, 
MDA-MB-231 cell line, also derived from a pleural 
effusion [34], represents a more aggressive breast tumor. 
This triple-negative cell line was classified as claudin-low 
[17]. Both cell lines are well accepted breast cancer in 
vitro models. They were selected not only because they 
represent opposite types of tumor, but also because MCF-7 
is a hormone dependent model, and MDA-MB-231 is an 
independent one. On the other hand, the MCF-10A cell line 
arose from a breast cyst of a premenopausal woman [35] 
and has been considered triple negative [36]. HBL-100, 
not tumorigenic at low passages, was originally isolated 
from the milk of an apparently healthy woman [37] and 
has been classified as claudin-low [17]. Both cell lines are 
well-accepted models of a non-tumor breast.
In this work, Epi was chosen since it preferentially 
binds to β2-AR (and NEpi to β1-AR) and this receptor 
is the main β subtype expressed in both tumor and non-
tumorigenic breast cells [14, 19, 38, 39]. Epi plasma 
concentration is extremely variable when comparing data 
from the literature. However, its basal concentration is 
around 1 nM which can rise 10-fold within seconds during 
acute stress [7, 40]. For this reason, we decided to evaluate 
the effect of two different Epi concentrations (1 nM and 
1μM). Interestingly, when investigating the effect of Epi in 
cell proliferation, adhesion and migration, the action was 
opposite in the non-tumorigenic and the tumor cells. In 
MCF-10A and HBL-100, Epi tended to maintain a benign 
phenotype, decreasing cell proliferation and migration, 
and stimulating cell adhesion. The same behavior was 
observed when cells were stimulated with the β-agonist, 
Iso. On the other hand, Epi induced cell proliferation and 
cell migration on MCF-7 tumor cells. This effect on cell 
proliferation is mediated by α2-AR, as we have previously 
described [18]. Moreover, in this study dexmedetomidine, 
an α2-agonist, also induced a decrease in MDA-MB-231 
cell adhesion, and an increase in cell migration in both 
tumor cell lines. In particular, in MCF-7, when increasing 
Epi concentration to 1 μM, no significant differences were 
observed in terms of cell migration. This could be due to 
the fact that at nM concentration, actions are mediated 
preferentially by α2-AR, and at μM concentration the 
β-AR effect compensates for the α2-AR effect. This dual 
Epi action, was previously described in the proliferation 
of breast cancer cell lines [9]. In conclusion, Epi response 
could then be interpreted as mainly mediated by β-AR in 
non-tumorigenic cells and by α2-AR in tumor cells.
ARs are widely over-expressed in numerous types 
of human breast tumor. In particular, an enhanced β2-AR 
expression was found in the luminal subtype with low 
clinical stage, low proliferation and good prognosis [41]. 
In line with this, the present study shows that the non-
tumorigenic MCF-10A cell line express higher levels of 
β-AR than the tumor MCF-7 cell line. On the other hand, 
Powe et al. described that α2C-AR are highly expressed in 
breast tumors with a more aggressive phenotype, which is 
in line with our previous observation where α2-AR binding 
sites were higher in tumor breast cell lines in comparison 
with the non-tumorigenic cells [18].
cAMP production is the classical second messenger 
involved in the β-AR pathway. Therefore, we determined 
its levels in the non-tumorigenic and tumor breast cell 
lines. cAMP levels were higher in the non-tumorigenic 
MCF-10A and HBL-100, intermediate in MCF-7 and 
lowest in MDA-MB-231. These findings suggest that there 
seems to be a progression toward less cAMP production 
when the cells are more malignant. This is in line with 
Bodwin et al, who demonstrated, even before breast 
cancer β-AR description, that cAMP inhibits mammary 
tumor growth [42]. MDA-MB-231 cell line was described 
as expressing high levels of β2-AR [22]. However, as 
previously mentioned, low cAMP levels were detected. 
Therefore, in this cell line, the production of this second 
messenger does not seem to directly correlate with β2-AR 
concentration. Indeed, it is well known that the activity 
of GPCRs results from a coordinated balance among 
diverse mechanisms that govern receptor signaling at the 
different levels of signal propagation. Thus, our findings 
in the MDA-MB-231 cells could be explained by an 
imbalance in protein levels involved in the β-signaling 
pathway or an impaired coupling of the β2-AR/G protein/
adenylyl cyclase. Further detailed studies are necessary to 
determine the cause of these low cAMP levels detected in 
MDA-MB-231 cells.
cAMP concentration is the result of its production, 
which is diminished by desensitization, its degradation 
by phosphodiesterases (PDEs) and/or the efflux by 
multidrug resistance-associated proteins. In particular, 
desensitization has been extensively studied for the 
β2-AR. It was described as a physiologically mechanism 
triggered by constant or repeated stimuli, which protects 
the cell from both short- and long-term receptor 
overstimulation [43]. The results of cAMP production 
showed that MCF-10A and MCF-7 produced higher 
levels of this cyclic nucleotide within non-tumorigenic 
or tumor cell categories. Thus, these two cell lines were 
chosen in order to evaluate the role of β2-AR on the tumor 
phenotype. Since MCF-10A showed higher β2-AR and 
cAMP levels than MCF-7, we then focused on studying 
β-desensitization, a process that directly associates cAMP 
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levels to functional β-AR in cell membrane. No differences 
were observed in the capacity of the endogenous receptor 
to continue being stimulated, assessed as a measure of 
all these processes summarized as desensitization. The 
time-course of cAMP production showed a parallel curve, 
suggesting that the degradation should also be similar in 
both cell lines. Therefore the higher cAMP concentration 
in MCF-10A cells seems to be due to a higher production 
in this cell line, which should be at least partially due 
to the higher β2-AR concentration observed. However, 
a better coupling of the receptor to the G protein and 
adenylyl cyclase cannot be discarded.
To further investigate the effect of β2-AR 
concentration in the breast cell phenotype, this receptor 
was successfully over-expressed or knocked-down in 
MCF-10A and MCF-7 cell lines, as confirmed by the 
binding assays. A strong effect on cell proliferation, 
adhesion and migration was observed in both cell lines 
when the β2-AR was silenced or over-expressed. These 
findings strengthen β2-AR relevance in cell processes 
implied in tumor progression. When MCF-10A cells were 
stimulated with the β-AR agonist, cAMP production highly 
correlated with cell proliferation, adhesion and migration. 
However, the basal levels were not modified by over-
expressing or silencing β2-AR. This could be explained 
by cAMP compartmentalization. In fact, it has recently 
been described that the proximity of PDEs to the site of 
cAMP synthesis restricts its dissemination through the 
cell [44]. Moreover, the stimulation of β1-AR induces a 
cAMP gradient that propagates throughout the cells, 
while localized β2-AR stimulation does not trigger cAMP 
diffusion [45]. On the other hand, classical approaches to 
measuring total cAMP production with poor spatiotemporal 
resolution most probably miss cAMP synthesis in discrete 
cell compartments. All in all, in MCF-10A cells slight 
changes of cAMP levels in specific cell compartments 
could translate into important changes in biological 
actions. In MCF-7 cells however, the over-expression of 
the receptor enhanced both the basal and the stimulated 
cAMP levels, showing an important basal activity of the 
receptor in these cells. Unliganded β2-AR was described 
coupling to Gs, explaining the basal activity [46].
Experiments investigating the possibility of using α2 
and β-agonists and antagonists for inhibiting cell migration 
and invasion and enhancing cell adhesion are advanced in 
our laboratory, as well as the signaling pathways involved 
in these processes.
In conclusion, the present study demonstrates for 
the first time that not only activation, but also β2-AR 
expression regulates breast tumor cell phenotype, 
modifying proliferation, adhesion and cell migration. Thus, 
the level of β2-AR expression and its functionality could be 
important indicators of cell malignancy and consequently 
of tumor progression. Additionally, as similar results were 
obtained in two different and opposite tumor models, 
the role of β2-AR in breast cancer might be independent 
of the breast cancer molecular subtype reinforcing 
its relevance in clinical translation. Future studies 
using patient and normal breast samples are necessary 
to gain greater insight for the implication of β2-AR 
on breast cancer.
MATERIALS AND METHODS
Drugs and reagents
Methyl-[3H]-thymidine (NET 027E; specific 
activity: 20 Ci/mmol) was from Dupont-New England 
Nuclear (Boston, MA, USA). [3H]-cAMP (31 Ci/mmol) 
and [3H]-CGP12177 (30 Ci/mmol) were from Perkin 
Elmer Life Sciences (Waltham, MA, USA). Insulin, 
epidermal growth factor (EGF), hydrocortisone, 
(-)epinephrine, isoproterenol, 3-isobutyl-methylxantine, 
were from Sigma-Aldrich (St Louis, MO, USA). 
Dexmedetomidine was purchased from Abbot (Buenos 
Aires, Argentine). Culture medium, fetal calf serum 
(FCS), Lipofectamine 2000, siRNA (ADRB2 Stealth 
Select RNAi™, HSS100258, HSS100259, y HSS100260) 
and other products for cell culture were from Invitrogen 
(Carlsbad, CA, USA). FuGENE® was purchased from 
Promega (Madison, WI, USA) and the transwell inserts 
were BD-Falcon (San Jose, CA, USA).
Cell culture and transfection
MCF-10A, MCF-7, MDA-MB-231 and HBL-100 
cells lines were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and were 
cultured as already described [18] with Hepes-buffered 
DMEM/Ham F12 culture medium (basal medium) 
supplemented with antibiotics (100 μg/mL streptomycin, 
100 IU/mL penicillin), 10% FCS and 2 μg/mL human 
insulin (complete medium). For MCF-10A cells the 
medium was also supplemented with 20 ng/mL EGF and 
0.1 μM hydrocortisone. Cells were sub-cultured once 
weekly by trypsinization (0.25% trypsin–0.025% EDTA) 
and the medium was changed every second or third day.
For transfection, 5x105 cells/well were seeded in 
24 well-plates in complete medium. The receptors were 
knocked down with small interfering RNA (siRNA) 
as previously described [23]: 10 nM of three different 
sequences of siRNA targeting β2-AR, the mixture of them 
or 10 nM non-targeting scrambled siRNA (sc), used as 
a control. The β2-AR was overexpressed by transfecting 
1.5 μg per well of a plasmid already described [24]. 
The control was the empty vector pcDNA3.1 (mock). 
The plasmids and siRNAs were prepared in OPTIMEM 
medium. For MCF-10A cells, FuGENE was used for 
18 h [14], whereas for MCF-7 cells Lipofectamine 
2000 was used for 6 h. After transfection, the medium 
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was removed and replaced by fresh complete medium. 
Proliferation, adhesion and migration assays were 
performed between 48 and 72 h post-transfection. 
Receptor silencing or over-expression was evaluated by 
binding assays.
Cell proliferation
Cells were seeded in 96-well plates (5x103 cells/
well) and grown during 24 h in complete medium. After 
24 h the medium was changed to 2% charcoal-stripped 
FCS and the cells were treated with the compounds 
described. The treatment was repeated an additional day 
with the addition of 0.2 μCi methyl-[3H]-thymidine/
well. Cells were harvested in a Nunc Cell Harvester 
8 and radioactive nuclei retained into the glass fiber filters 
were counted in a liquid scintillation counter. The results 
are expressed as percentage of the control incubated in 
the absence of any compound. Proliferation response in 
transfected cells was evaluated by automatic cell-counting 
(Beckman Coulter Z1 Cell-counter).
Measurement of cell adhesion
Cells were seeded in 12-well plates (1.5x105 cells/
well) for 24 h, the medium was removed, and cells were 
treated or not with different adrenergic compounds during 
15 min in basal medium. The medium was removed and 
the cells were incubated in Mg2+/Ca2+-free PBS containing 
0.5 mM EDTA and 0.25% trypsin as previously described 
in constant agitation at room temperature during 15 min for 
MCF-10A cells [14], or 5 min for MCF-7, MDA-MB-231 
and HBL-100 cells. Cells that resisted the treatment and 
remained adherent to the plastic were harvested following 
an additional 30 min incubation in Mg2+/Ca2+-free PBS 
containing 2.5 mM EDTA and 1.25% trypsin and counted 
(attached cells) using a cell counter. The percentage of 
adherent cells was calculated as follows: attached cells × 100/ 
(attached cells + detached cells).
Migration assay
Cell migration was evaluated using transwell 
inserts with 8 μm pore. 2x104 cells were seeded in the 
upper compartment, onto the porous membrane, and 
were allowed to adhere during 4 h in complete medium. 
Afterwards, the medium was carefully removed and 
changed for a basal medium and stimulated with the 
adrenergic compounds to test. After 16 h, the medium was 
removed and the cells fixed and stained with 0.05% crystal 
violet in methanol during 10 min. Non-migrated cells were 
removed from the top of the membrane using a cotton 
swab. The total amount of migrated cells was counted on 
an inverted microscope.
Radioligand binding assay
β-AR quantification was performed by binding 
analysis in whole cells at 4 °C to avoid ligand internalization, 
as described [23]. 7x104 cells/well were seeded in 48 well 
plates. The number of binding sites was evaluated using 
the antagonist [3H]-GCP12177 in the presence or absence 
of 100 μM Iso at 4 °C [23]. The incubation was stopped 
by dilution with 3 ml of ice-cold 50 mM Tris-HCl, pH 7.4. 
After three washes with 3 ml of ice-cold buffer, the bound 
fraction was collected in 200 μl of ethanol.
cAMP cell content quantification
cAMP content was quantified using a competitive 
radio-binding assay for PKA using [3H]-cAMP, as 
previously described [47]. Cells were seeded in 24-well 
plates (1.7x105 cells/well) in complete medium. After 
24 h, the medium was removed and cells were incubated 
in RPMI medium without phenol red at 37 °C with 
different adrenergic compounds during the indicated times 
with or without 1mM of the PDE inhibitor 3-isobutyl-
methylxantine (IBMX) at 37 °C. Ethanol was added to 
stop the reaction. The extracts were centrifuged for 3 min 
at 3000×g and the recovered supernatant was evaporated 
and then resuspended in 50 mM Tris-HCl, pH 7.4, 0.1% 
BSA for cAMP quantification. Standard curves were 
performed with 8 different cAMP concentrations, ranging 
from 0.1 to 90 pmols. The data shown are the result of 
duplicates from at least three independent experiments.
Statistical analysis
The experiments were repeated at least twice with 
identical results. The analyses performed were Student’s 
t test or ANOVA followed by Bonferroni or Dunnet’s 
test in the case of multiple comparison. The differences 
were considered significant when p<0,05 [48]. Binding 
data, sigmoidal dose-response, and desensitization fittings 
were performed with GraphPad Prism 5.00 for Windows 
(GraphPad Software, San Diego, CA).
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